No Data
Oppenheimer Starts ArriVent BioPharma at Outperform
Alvotech Launches First Biosimilar of J&J's Stelara in Europe
Sector Update: Health Care Stocks Rise in Monday's Premarket Hours
Health care stocks were advancing premarket Monday with the Health Care Select Sector SPDR Fund (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) up 0.5% recently.IQVIA Holdings (IQV) was up
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Monday, Addex Therapeutics (NASDAQ:ADXN) announced its partner Janssen Pharmaceuticals, Inc, a unit of Johnson & Johnson (NYSE:JNJ), has discontinued the development of ADX71149 (JNJ-40411813) in
Johnson & Johnson Seeks FDA OK of Spravato as Monotherapy
Johnson & Johnson is seeking Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression.
Express News | Johnson & Johnson Submits Supplemental New Drug Application To FDA Seeking Approval Of SPRAVATO CIII Nasal Spray In Treatment-Resistant Depression
muhamad Hazairudin s : Muhammad Hazairudin Shadan